David H. Walker's research while affiliated with University of Texas Medical Branch at Galveston and other places

What is this page?


This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.

It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.

If you're a ResearchGate member, you can follow this page to keep up with this author's work.

If you are this author, and you don't want us to display this page anymore, please let us know.

Publications (441)


FIGURE 1. Past-Presidents (from left) Jim Kazura, Julie Jacobson, and David Walker.
FIGURE 2. Past-Presidents (from left) Chandy John, Regina Rabinovich, and Dan Bausch.
A Forward Look from the Society’s Present and Past Presidents: A Transcript from the 2023 ASTMH Annual Meeting
  • Article
  • Full-text available

May 2024

·

8 Reads

The American journal of tropical medicine and hygiene

Daniel G. Bausch

·

·

·

[...]

·

David H. Walker
Download
Share


Variant mutation in SARS-CoV-2 nucleocapsid enhances viral infection via altered genomic encapsidation

March 2024

·

52 Reads

The evolution of SARS-CoV-2 variants and their respective phenotypes represents an important set of tools to understand basic coronavirus biology as well as the public health implications of individual mutations in variants of concern. While mutations outside of Spike are not well studied, the entire viral genome is undergoing evolutionary selection, particularly the central disordered linker region of the nucleocapsid (N) protein. Here, we identify a mutation (G215C), characteristic of the Delta variant, that introduces a novel cysteine into this linker domain, which results in the formation of a disulfide bond and a stable N-N dimer. Using reverse genetics, we determined that this cysteine residue is necessary and sufficient for stable dimer formation in a WA1 SARS-CoV-2 background, where it results in significantly increased viral growth both in vitro and in vivo . Finally, we demonstrate that the N:G215C virus packages more nucleocapsid per virion and that individual virions are larger, with elongated morphologies.


Interaction between host G3BP and viral nucleocapsid protein regulates SARS-CoV-2 replication and pathogenicity

March 2024

·

63 Reads

·

6 Citations

Cell Reports

G3BP1/2 are paralogous proteins that promote stress granule formation in response to cellular stresses, including viral infection. The nucleocapsid (N) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inhibits stress granule assembly and interacts with G3BP1/2 via an ITFG motif, including residue F17, in the N protein. Prior studies examining the impact of the G3PB1-N interaction on SARS-CoV-2 replication have produced inconsistent findings, and the role of this interaction in pathogenesis is unknown. Here, we use structural and biochemical analyses to define the residues required for G3BP1-N interaction and structure-guided mutagenesis to selectively disrupt this interaction. We find that N-F17A mutation causes highly specific loss of interaction with G3BP1/2. SARS-CoV-2 N-F17A fails to inhibit stress granule assembly in cells, has decreased viral replication, and causes decreased pathology in vivo. Further mechanistic studies indicate that the N-F17-mediated G3BP1-N interaction promotes infection by limiting sequestration of viral genomic RNA (gRNA) into stress granules.


The NSP3 protein of SARS-CoV-2 binds fragile X mental retardation proteins to disrupt UBAP2L interactions

January 2024

·

37 Reads

·

2 Citations

EMBO Reports

Viruses interact with numerous host factors to facilitate viral replication and to dampen antiviral defense mechanisms. We currently have a limited mechanistic understanding of how SARS-CoV-2 binds host factors and the functional role of these interactions. Here, we uncover a novel interaction between the viral NSP3 protein and the fragile X mental retardation proteins (FMRPs: FMR1, FXR1-2). SARS-CoV-2 NSP3 mutant viruses preventing FMRP binding have attenuated replication in vitro and reduced levels of viral antigen in lungs during the early stages of infection. We show that a unique peptide motif in NSP3 binds directly to the two central KH domains of FMRPs and that this interaction is disrupted by the I304N mutation found in a patient with fragile X syndrome. NSP3 binding to FMRPs disrupts their interaction with the stress granule component UBAP2L through direct competition with a peptide motif in UBAP2L to prevent FMRP incorporation into stress granules. Collectively, our results provide novel insight into how SARS-CoV-2 hijacks host cell proteins and provides molecular insight into the possible underlying molecular defects in fragile X syndrome.




SARS-CoV-2 hijacks fragile X mental retardation proteins for efficient infection

September 2023

·

63 Reads

Viruses interact with numerous host factors to facilitate viral replication and to dampen antiviral defense mechanisms. We currently have a limited mechanistic understanding of how SARS-CoV-2 binds host factors and the functional role of these interactions. Here, we uncover a novel interaction between the viral NSP3 protein and the fragile X mental retardation proteins (FMRPs: FMR1 and FXR1-2). SARS-CoV-2 NSP3 mutant viruses preventing FMRP binding have attenuated replication in vitro and have delayed disease onset in vivo . We show that a unique peptide motif in NSP3 binds directly to the two central KH domains of FMRPs and that this interaction is disrupted by the I304N mutation found in a patient with fragile X syndrome. NSP3 binding to FMRPs disrupts their interaction with the stress granule component UBAP2L through direct competition with a peptide motif in UBAP2L to prevent FMRP incorporation into stress granules. Collectively, our results provide novel insight into how SARS-CoV-2 hijacks host cell proteins for efficient infection and provides molecular insight to the possible underlying molecular defects in fragile X syndrome.


Antibody response kinetics of one dose Ad26.COV2 (10⁸ or 10¹⁰ vp) and two doses BNT162b2 (5 μg/each) vaccines in Syrian hamsters
Four-to-five-week-old male Syrian hamsters were immunized with one 10⁸ or 10¹⁰ vp dose of the Ad26.COV2.S vaccine (n = 49 and 50, respectively), two 5 μg doses of the BNT162b2 vaccine (n = 50), or sham-vaccinated (PBS; n = 59) and followed through 252 days post-vaccination (dpv). a Experimental design, showing the immunizations and blood collections. b–d Serum neutralizing antibody responses through 252 dpv after (b) 10¹⁰ vp of Ad26.COV2.S, (c) 10⁸ vp of Ad26.COV2.S, or (d) two 5 μg doses of BNT162b2 as determined by plaque reduction neutralization tests (PRNT) based on a 50% or greater reduction in plaque counts (PRNT50) against the USA_WA1/2020 strain (n = 20/per group). e–g Serum binding antibody responses through 252 dpv after (h) 10¹⁰ vp of Ad26.COV2.S, (i) 10⁸ vp of Ad26.COV2.S, or (j) two 5 µg doses of BNT162b2 as determined by optical density at 490 nm (OD490 nm) in an ELISA measuring anti-S1 (USA_WA1/2020) IgG (n = 20/per group). h–j Serum binding antibody responses through 252 dpv after (e) 10¹⁰ vp of Ad26.COV2.S, (f) 10⁸ vp of Ad26.COV2.S, or (g) two 5 µg doses of BNT162b2 as determined by area under the curve (AUC) kinetics in an ELISA measuring anti-S1 (USA_WA1/2020) IgG (n = 20/per group). For panels b–d and h–j, points represent individual subjects, fitted curves reflect the Fit Spline algorithm, dotted lines represent the lower limit of detection, and numbers represent the geometric mean titers (GMTs) at a given timepoint. For panels e–g, data are presented as GMTs, error bars represent the 95% confidence interval, and fitted curves reflect the Sigmoidal 4-Parameter Logistic (4PL) regression algorithm. Panel a was created with BioRender.com. Panels b–j were generated using GrapPad Prism v9.4 software. See Source Data for complete data and Supplementary Fig. 2 for complete vaccination regimens scheme.
Booster dose of NVX-CoV2373 enhanced neutralizing antibody responses against BA.5 in hamsters primarily vaccinated with Ad26.COV2.S or BNT162b2
Four-to-five-week-old male hamsters were immunized either with one dose (10¹⁰ or 10⁸ vp) of Ad26.COV2.S or two doses of BNT162b2 (5 μg per dose). After 6 months (day 168), animals were boosted with heterologous vaccines: 0.5 µg mRNA-1273 (n = 12 per group) or 1 μg rS/15 μg Matrix-M NVX-CoV2373 (n = 12 per group), or with the homologous vaccines: 10⁸ vp Ad26.COV2.S (n = 12 per group) or 0.5 μg BNT162b2 (n = 12). A sham-boosted group (PBS) was included for comparison (n = 13 for 10⁸ vp of Ad26.COV2.S or n = 14 for 10¹⁰ vp of Ad26.COV2.S and BNT162b2 groups). Blood was collected immediately prior to boosting as well as at 1 and 3 months post-boost (days 196 and 252). Neutralizing antibody titers against Omicron BA.5 were determined by foci reduction neutralization assay (FRNT), with the FRNT50 values defined as the maximum serum dilution to neutralize at least 50% of infectious virus. a–c Paired analysis of pre-boost, 1 month post-boost, and 3 months post-boost serum neutralizing titers against Omicron BA.5 from hamsters that received as primary immunizations (a) 10¹⁰ vp Ad26.COV2.S, (b) 10⁸ vp Ad26.COV2.S, or (c) two 5 μg doses of BNT162b2. d–f Grouped analysis of serum neutralizing antibody responses of samples collected pre-boost, 1 month post-boost and 3 months post-boost against BA.5 in hamsters that received as primary immunizations (d) 10¹⁰ vp Ad26.COV2.S, (e) 10⁸ vp Ad26.COV2.S, or (f) two 5 μg doses of BNT162b2. Colors designate experimental cohorts, data points represent individual subjects, bar heights represent the geometric mean titer (GMT), error bars represent the 95% confidence interval, and dotted lines represent the lower limit of detection. GMTs and fold-change values are noted above the respective cohorts. Groups were compared by non-parametric ANOVA (Friedman’s test) with Dunn’s multiple comparison post-test (ns = not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). All panels were generated using GrapPad Prism v9.4 software. See Source Data for complete data.
Booster dose of NVX-CoV2373 enhances protection against BA.5 infection of Golden hamsters after primary vaccination with one dose of Ad26.COV2.S or two doses of BNT162b2
Four-to-five-week-old male hamsters were immunized either with one dose (10¹⁰ or 10⁸ vp) of Ad26.COV2.S or two doses of BNT162b2 (5 μg per dose) vaccines. After 6 months (day 168), animals were boosted with heterologous vaccines: (0.5 µg mRNA-1273 or 1 μg rS/15 μg Matrix-M NVX-CoV2373), or with the homologous vaccines (10⁸ vp Ad26.COV2.S or 0.5 μg BNT162b2). Sham-vaccinated and sham-boosted groups were included for comparison. At 3 months post-boost, hamsters were challenged with Omicron BA.5 or mock (PBS). a Schematic diagram of immunizations, blood draws, and virus challenge. b Change in body weight (n = 129 at 0–2 dpi, n = 80 at 3-4 dpi). c–e Infectious virus titers at 2 and 4 dpi in (c) nasal washes, (d) trachea, and (e) lungs after BA.5 or mock challenge. Data are organized based on the primary vaccination with 10¹⁰ vp of Ad26.COV2.S (left), 108 bp of Ad26.COVV2.S (center), or two 5 μg doses of BNT162b2 (right) vaccines; sham data for the Ad26.COVV2.S groups were identical but different from the BNT162b2 group. Colors designate experimental cohorts (n = 6–8 subjects per group). In panel B, data points represent the sample means and error bars represent the standard deviations. In panels c–e, data points represent individual subjects, bar heights represent the sample means, error bars represent the standard deviations, and dotted lines represent the lower limit of detection. Groups were compared by one-way ANOVA with Tukey’s post-test (ns = not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Panel A was created with BioRender.com. Panels B–E were generated using GraphPad Prism v9.4 software. See Source Data for complete data.
Histopathology of lungs of vaccinated and boosted hamsters challenged with Omicron subvariant BA.5
Representative hematoxylin and eosin (H&E) images of the left lung of hamsters 4 days after intranasal challenge with 10⁴ PFU of BA.5. a, b H&E staining of lung sections harvested from sham-vaccinated (a, left; scale bar 100 μM) and mock-infected (a, right, scale bar 100 μM) or vaccinated and boosted animals (b; scale bar 100 μM) at 4 dpi with BA.5. A section from a sham-vaccinated and a mock-challenged animal are shown for comparison. The representative images are from four lung sections per animal from n = 4–5 per group. See Source Data for the complete histopathological evaluation of each specimen.
Correlation between neutralizing antibody titers and protection against BA.5
a–i Correlation between the FRNT50 neutralization titers at 3 months post-boost (pre-challenge) against BA.5 (x-axis) and the infectious virus loads (y-axis) detected at 4 dpi in (a, d, g) nasal washes, (b, e, h) trachea, and (c, f, i) lungs of hamsters primed with (a–c) one 10¹⁰ vp dose of Ad26.COV2.S (n = 6 or 7 per group), (d–f) one 10⁸ vp dose of Ad26.COV2.S (n = 6 or 7 per group), or g–i two 5 μg doses of BNT162b2 (n = 6 or 7 per group). j Proportion of hamsters developing breakthrough infections following BA.5 challenge. Percentage (%) and number of animals with detectable infectious virus loads in at least one sample (nasal wash, trachea, and/or lungs) are shown below each graph. Colors designate experimental cohorts (n = 6–7 animals per group). In panels a–i, data points represent individual animals, thick lines represent linear regression, dashed lines with shading represent 95% CI, and dotted lines represent the lower limit of detection for each assay. Spearman’s rank correlation coefficient (r) and p-values are shown. In panel j, the color-coded portion of the ring represents the proportion of hamsters developing a breakthrough infection following BA.5 challenge. Panels were generated using GraphPad Prism v9.4 software. See Source Data for complete data.
Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters

July 2023

·

146 Reads

·

4 Citations

Nature Communications

The SARS-CoV-2 Omicron subvariant BA.5 rapidly spread worldwide and replaced BA.1/BA.2 in many countries, becoming globally dominant. BA.5 has unique amino acid substitutions in the spike protein that both mediate immune escape from neutralizing antibodies produced by immunizations and increase ACE2 receptor binding affinity. In a comprehensive, long-term (up to 9 months post primary vaccination), experimental vaccination study using male Syrian hamsters, we evaluate neutralizing antibody responses and efficacy against BA.5 challenge after primary vaccination with Ad26.COV2.S (Janssen) or BNT162b2 (Pfizer/BioNTech) followed by a homologous or heterologous booster with mRNA-1273 (Moderna) or NVX-CoV2373 (Novavax). Notably, one high or low dose of Ad26.COV2.S provides more durable immunity than two primary doses of BNT162b2, and the NVX-CoV2373 booster provides the strongest augmentation of immunity, reduction in BA.5 viral replication, and disease. Our data demonstrate the immunogenicity and efficacy of different prime/boost vaccine regimens against BA.5 infection in an immune-competent model and provide new insights regarding COVID-19 vaccine strategies.


Interaction between host G3BP and viral nucleocapsid protein regulates SARS-CoV-2 replication

June 2023

·

104 Reads

·

6 Citations

G3BP1/2 are paralogous proteins that promote stress granule formation in response to cellular stresses, including viral infection. G3BP1/2 are prominent interactors of the nucleocapsid (N) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the functional consequences of the G3BP1-N interaction in the context of viral infection remain unclear. Here we used structural and biochemical analyses to define the residues required for G3BP1-N interaction, followed by structure-guided mutagenesis of G3BP1 and N to selectively and reciprocally disrupt their interaction. We found that mutation of F17 within the N protein led to selective loss of interaction with G3BP1 and consequent failure of the N protein to disrupt stress granule assembly. Introduction of SARS-CoV-2 bearing an F17A mutation resulted in a significant decrease in viral replication and pathogenesis in vivo, indicating that the G3BP1-N interaction promotes infection by suppressing the ability of G3BP1 to form stress granules.


Citations (58)


... In a recent study comparing the interactomes of different β-coronavirus strains, FXRs were identified as Nsp3-interacting proteins specifically in SARS-CoV-2 and SARS-CoV (Almasy et al., 2021;Garvanska et al., 2024). The amino acid sequences of the FXR1-binding sites in Nsp3 identified in our study are conserved in SARS-CoV, but not in MERS, hCoV-229E, or hCoV-OC43 (Fig. S5 O). ...

Reference:

LLPS of FXR proteins drives replication organelle clustering for β-coronaviral proliferation
The NSP3 protein of SARS-CoV-2 binds fragile X mental retardation proteins to disrupt UBAP2L interactions
  • Citing Article
  • January 2024

EMBO Reports

... Throughout the pandemic, small animal models have been used extensively to assess the virulence of wild type SARS-CoV-2 and emerging VOCs [8,15,[17][18][19][20][21][22][23][24][25][26][27]. These studies have provided invaluable data on disease pathogenesis, virus transmission and the efficacy of different anti-viral compounds or vaccines [20,[28][29][30][31][32][33]. Importantly, hamsters have been shown to be naturally susceptible to SARS-CoV-2 infection and to be able to transmit the virus to humans [34]. ...

Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters

Nature Communications

... The protein arginine methyltransferase (PRMT) 5, 6, 7, and 9 genes were significantly down-regulated by PAV-104 treatment, and members of the PRMT family are known to methylate N 17 . Lastly, G3BP1, downregulated by PAV-104 treatment, is known to be sequestered by SARS-CoV-2 N, leading to suppression of the host immune response to favor virus replication 44 . ...

Interaction between host G3BP and viral nucleocapsid protein regulates SARS-CoV-2 replication

... They may also be the reason why VOC Omicron appears to be more poorly cleaved than VOC Delta and the Wuhan strain [53]. The N679K mutation, which was found in all VOC Omicron sequences, appears linked to reduced spike expression levels in host cells and showed a preference for transmission through the upper airways when compared to the Wuhan strain [64]. However, the other mutations in VOC Omicron such as N655Y and P681H have been shown to increase spike processing. ...

Loss-of-function mutation in Omicron variants reduces spike protein expression and attenuates SARS-CoV-2 infection

... Multiple secondary plant metabolites have been reported to be used for the treatment of MDR pathogens. But these [99] The above vaccines have their own short comings either it may provide strong protection against homologous challenge but weak protection against heterologous challenge or it may provide active immunity by sustaining antibodies for only a short duration which diminishes through time [100]. In humans, homologous immunity lasts up to 3.5 years but heterologous immunity lasts only a few months and humans can get infected by multiple strains simultaneously [99]. ...

A scrub typhus vaccine presents a challenging unmet need

npj Vaccines

... Recent studies showing nsp16 regulating IFN-I-mediated innate immune pathways, by Russ et al. and Schindewolf et al., are similar to our work. 50,51 They found that defect of SARS-CoV-2 nsp16 function (K-D-K-E mutations) attenuates viral replication in a IFN-Idependent manner. Mechanistically, they demonstrated the necessity of IFIT-1 and IFIT-3 in mediating nsp16 mutant attenuation. ...

SARS-CoV-2 Uses Nonstructural Protein 16 To Evade Restriction by IFIT1 and IFIT3
Journal of Virology

Journal of Virology

... In Colombia, no attempt to detect the bacterium or the exposition to it was made until 2022, when a study found seropositivity to Orientia spp., confirmed with Western blot, among inhabitants of four municipalities of Cauca department (Table 2) ( Figure 1J) [99], which should encourage to perform more studies to establish if Orientia is part of febrile illnesses in the region, and if so, determine which species are involved, as well as its possible implications for Colombian public health or whether further surveillance by local health systems is warranted. ...

Serologic Evidence of Orientia Infection among Rural Population, Cauca Department, Colombia

Emerging Infectious Diseases

... The higher-than-expected seroreactivity to R. typhi within other endemic and previously endemic areas supports this possibility. 16,17 The evidence suggesting flea-borne typhus is underrecognized in Southern California has broad implications. Yes, flea-borne typhus has been described as mild, but patients infected with R. typhi tend to disagree with this sentiment. ...

Increased Seroprevalence of Typhus Group Rickettsiosis, Galveston County, Texas, USA

Emerging Infectious Diseases

... Prior microarray research of monocytes and MФs in human scrub typhus suggested that this infection triggers antiviral-like immune programs with elevated IFN-mediated responses [23,24]. We also reported the extremely upregulated levels of IFN-γ, TNF-α, IFN-γ-regulated CXCR chemokines (CXCL9, CXCL10, CXCL11) in the lungs, spleen, liver, and brain of Karpinfected B6 and CD-1 mice [12,25,26]. Mouse brain RNAseq confirmed activated signaling pathways for IFN responses, defense response to bacteria, immunoglobulin-mediated immunity, the IL-6/JAK-STAT axis, and the TNF/NF-κB axis [27]. ...

Host transcriptomic profiling of CD-1 outbred mice with severe clinical outcomes following infection with Orientia tsutsugamushi

... 1 In recent years, a noticeable increasing trend in the prevalence of tickborne infectious diseases has been emphasized and attributed to a wide range of pathogens transmitted by ticks with a high vectorial capacity. 2,3 The R. sanguineus, the prominent vector for transmitting Babesia vogeli, Ehrlichia canis, and Rickettsia conorii, affect animal health and cause economic losses. [4][5][6][7] The larva, nymph and adult of the three-host tick R. sanguineus all engorge primarily on dogs, occasionally attach to humans and feed on different hosts for each life stage. ...

A Vaccine for Canine Rocky Mountain Spotted Fever: An Unmet One Health Need